1
|
Huet F, Mariano-Goulart D, Aguilhon S, Delbaere Q, Lacampagne A, Fauconnier J, Leclercq F, Macia JC, Akodad M, Jammoul N, Prunier F, Mewton N, Angoulvant D, Lozza C, Soltani S, Rodier A, Grandemange S, Dupuy AM, Cristol JP, Amico M, Nagot N, Roubille F. Colchicine to prevent sympathetic denervation after acute myocardial infarction: the COLD-MI trial. Eur Heart J 2024; 45:725-727. [PMID: 38289979 DOI: 10.1093/eurheartj/ehae042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Revised: 11/27/2023] [Accepted: 01/16/2024] [Indexed: 02/01/2024] Open
Affiliation(s)
- Fabien Huet
- Department of Cardiology, Vannes Regional Hospital, 20 Bd Général Maurice Guillaudot, 56000 Vannes, France
- Department of Cardiology, Montpellier University Hospital, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
| | - Denis Mariano-Goulart
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
- Department of Nuclear Medecine, Montpellier University Hospital, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
| | - Sylvain Aguilhon
- Department of Cardiology, Montpellier University Hospital, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
| | - Quentin Delbaere
- Department of Cardiology, Montpellier University Hospital, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
| | - Alain Lacampagne
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
| | - Jérémy Fauconnier
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
| | - Florence Leclercq
- Department of Cardiology, Montpellier University Hospital, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
| | - Jean-Christophe Macia
- Department of Cardiology, Montpellier University Hospital, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
| | - Mariama Akodad
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
- Institut cardiovasculaire Paris Sud, Hôpital Privé Jacques-Cartier, Ramsay Santé, 6 Av. du Noyer Lambert, 91300 Massy, France
| | - Nidal Jammoul
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
| | - Fabrice Prunier
- University Angers, UMR CNRS 6015, Inserm U1083, Unité MitoVasc, Team Carme, SFR ICAT, 2 rue Haute de Reculée, 49045 Angers cedex, France
- Department of Cardiology, Angers University Hospital, 4 Rue Larrey, 49933 Angers Cedex, France
| | - Nathan Mewton
- Heart Failure Department, Clinical Investigation Center, INSERM 1060 & 1407, Hospices Civils de Lyon, University Claude Bernard Lyon 1, 59 Bd Pinel, 69500 Bron, France
| | - Denis Angoulvant
- Cardiology Department and EA4245 Transplantation Immunologie Inflammation, CHRU de Tours & Université de Tours, Av. de la République, 37170 Chambray-lès-Tours, France
| | - Catherine Lozza
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
| | - Sonia Soltani
- Department of Cardiology, Montpellier University Hospital, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
| | - Annabelle Rodier
- Department of Public Health, Clinical Research Unit, CHU Montpellier, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
| | - Sylvie Grandemange
- Department of Public Health, Clinical Research Unit, CHU Montpellier, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
| | - Anne-Marie Dupuy
- Department of Biochemistry, University Hospital of Montpellier, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
| | - Jean-Paul Cristol
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
- Department of Biochemistry, University Hospital of Montpellier, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
| | - Mailis Amico
- Biostatistics and Research Unit, CHU Montpellier, Univ Montpellier, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
| | - Nicolas Nagot
- Biostatistics and Research Unit, CHU Montpellier, Univ Montpellier, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
| | - François Roubille
- Department of Cardiology, Montpellier University Hospital, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France
- INI-CRCT (Investigation Network Initiative Cardiovascular and Rénal Clinical Trialist), CHRU de Nancy - Hôpitaux de Brabois, 4 Rue du Morvan, 54500 Vandœuvre-lès-Nancy, France
| |
Collapse
|
2
|
Waksman R, Merdler I, Case BC, Waksman O, Porto I. Targeting inflammation in atherosclerosis: overview, strategy and directions. EUROINTERVENTION 2024; 20:32-44. [PMID: 38165117 PMCID: PMC10756224 DOI: 10.4244/eij-d-23-00606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 11/06/2023] [Indexed: 01/03/2024]
Abstract
Atherosclerosis is a chronic condition characterised by the build-up of plaque in the inner lining of the blood vessels and it is the main underlying cause of cardiovascular disease. The development of atherosclerosis is associated with the accumulation of cholesterol and inflammation. Although effective therapies exist to lower low-density lipoprotein cholesterol (LDL-C) levels, some patients still experience cardiovascular events due to persistent inflammation, known as residual inflammatory risk (RIR). Researchers have conducted laboratory and animal studies to investigate the measurement and targeting of the inflammatory cascade associated with atherosclerosis, which have yielded promising results. In addition to guideline-directed lifestyle modifications and optimal medical therapy focusing on reducing LDL-C levels, pharmacological interventions targeting inflammation may provide further assistance in preventing future cardiac events. This review aims to explain the mechanisms of inflammation in atherosclerosis, identifies potential biomarkers, discusses available therapeutic options and their strengths and limitations, highlights future advancements, and summarises notable clinical studies. Finally, an evaluation and management algorithm for addressing RIR is presented.
Collapse
Affiliation(s)
- Ron Waksman
- MedStar Heart & Vascular Institute, MedStar Washington Hospital Center, MedStar Georgetown University Hospital, Washington, D.C., USA
| | - Ilan Merdler
- MedStar Heart & Vascular Institute, MedStar Washington Hospital Center, MedStar Georgetown University Hospital, Washington, D.C., USA
| | - Brian C Case
- MedStar Heart & Vascular Institute, MedStar Washington Hospital Center, MedStar Georgetown University Hospital, Washington, D.C., USA
| | - Ori Waksman
- MedStar Heart & Vascular Institute, MedStar Washington Hospital Center, MedStar Georgetown University Hospital, Washington, D.C., USA
| | - Italo Porto
- Department of Internal Medicine, University of Genoa, Genoa, Italy
- Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino - Italian IRCCS Cardiology Network, Genoa, Italy
| |
Collapse
|